Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Oral meds good for controlling Type II diabetes in children

17.08.2005


Oral medications may control symptoms of Type II diabetes in children just as well as insulin injections, a new study reports.



According to the medical records of 26 children diagnosed with the disease, oral medications reduced levels of a compound in the blood called hemoglobin A1C by an average of 2 percentage points.

A 2-percentage-point reduction is enough to decrease serious health risks and symptoms associated with Type II diabetes, said Milap Nahata, the study’s principal investigator and a professor of pharmacy and pediatrics at Ohio State University .


High blood sugar levels leave a diabetic vulnerable to developing heart and kidney disease and vision problems; symptoms include frequent urination and excessive thirst. Diabetics normally show high levels of hemoglobin A1C, which is a marker for blood sugar levels.

“This is the first study to show that oral medications may decrease these levels in children,” Nahata said.

The researchers wanted to compare the effectiveness of injected insulin to oral medications in lowering levels of this hemoglobin marker in children. Clear guidelines on the best treatments for children with Type II, or insulin-resistant, diabetes, have yet to be established, said Nahata.

“It’s only been within the last 20 years that we’ve seen large numbers of children developing this disease,” he said. “And most oral medications typically prescribed to children with the illness have never been compared to one another or to insulin.”

A common side effect of insulin is weight gain, which often discourages medication compliance among teenagers, Nahata said.

The results appear in a recent issue of the journal Pharmacotherapy.

In Type II diabetes the body’s cells don’t respond to insulin, the hormone that helps the body regulate blood sugar levels.

The researchers gathered five years’ worth of hemoglobin A1C values, medication and symptom data from the children’s medical records. All of the children lived in central Ohio . The average age was 15 for boys and 14 for girls.

Medications prescribed included insulin for some children and the oral drugs metformin and sulfonylurea. Some children took a combination of the drugs. While insulin and metformin are the only two drugs approved by the Food and Drug Administration for treating children with Type II diabetes, pediatricians have the authority to prescribe a different drug if they think it can do a better job of controlling a patient’s disease. It’s fairly common practice for doctors to do this, too.

“Fully 80 percent of the drugs on the market have never been studied adequately for use in children,” Nahata said.

In the study, the 14 children who were treated with insulin achieved the greatest reduction of the hemoglobin compound – from an average of 11.1 percent to 8.1 percent. Some of these children were also prescribed an oral drug.

“But the children treated with insulin also had the highest values to begin with,” Nahata said.

While normal hemoglobin A1C values range from 4 to 6 percent, reaching a value of 7 percent is considered a success for diabetics. But even reducing that value to 8 percent can cause a notable reduction in symptoms and risks associated with Type II diabetes.

According to the American Diabetes Association, the average diabetic has a hemoglobin A1C value of about 9 percent. Untreated, these levels can leave a person at serious risk for developing other health problems.

Values of the compound decreased from an average of 10.6 to 8 percent in the other 12 children who were prescribed the oral drugs only – a reduction comparable to those getting injections.

Half (13) of the children included in the study were able to lower the values of the hemoglobin compound to 7 percent or less. Another three children reduced their values to between 7 and 8 percent.

Type II diabetes is a disease that traditionally strikes overweight and obese adults. But more and more children have developed this disease due to childhood obesity rates nearly doubling in the past 20 years.

“Type II diabetes in children was almost unheard of when I started in pharmacy 30 years ago,” Nahata said. “It was supposed to be a disease that adults developed.”

Children are usually much more prone to developing Type I, or insulin-dependent, diabetes, a disease in which the pancreas does not produce enough insulin.

While Nahata says the results of this small study are interesting and may apply to the larger population, additional studies that include more patients are needed to compare the effectiveness of the drugs to each other for controlling the illness and its complications.

“We don’t yet know what the ideal drug or drug combination is for treating children with Type II diabetes,” Nahata said.

Children are at risk of developing Type II diabetes if

  • their body mass index (BMI, a measurement that relates weight to height) is above the 85th percentile for their age and sex;
  • they weigh 120 percent of their ideal weight;
  • have a parent or grandparent who also has the disease;
  • are African-American, Native American, Mexican American and Asian or Pacific Islander; and
  • show signs of insulin resistance.

Nahata conducted the study with Ohio State colleagues Jeffrey Striet and John Germak and with Sandra Benavides, who is with the University of Texas’ Pan American Cooperative Pharmacy Program.

Milap Nahata | EurekAlert!
Further information:
http://www.osu.edu

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>